Memuna Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -100.00%
- Profit Growth -10279.53%
- Ebitda -11915.62%
- Net Worth -26254.95%
- Total Assets 5385.76%
About Memuna Life Sciences
Memuna Life Sciences Private Limited (MLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 March 2019 (Five years and ten months 24 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Fakhruddin Khan, Kanthan Nagarajan, and Ehsanul Haque serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909DL2019PTC347130
-
Company No.
347130
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Mar 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Memuna Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Fakhruddin Khan
|
Director | 12-Mar-2019 | Current |
|
Kanthan Nagarajan
|
Director | 24-May-2019 | Current |
|
Ehsanul Haque
|
Director | 23-Feb-2023 | Current |
Financial Performance of Memuna Life Sciences.
Memuna Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 10279.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26254.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Memuna Life Sciences?
In 2023, Memuna Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Agrata Biotech LimitedKanthan Nagarajan is a mutual person
-
Jiovegan India Private LimitedFakhruddin Khan is a mutual person
-
Allianz Fmcg Industries Private Limited
Fakhruddin Khan is a mutual person
-
Verna Softech Limited
Kanthan Nagarajan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Memuna Life Sciences?
Unlock and access historical data on people associated with Memuna Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Memuna Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Memuna Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
